Showing 3941-3950 of 6772 results for "".
- Phase 3 Study Finds Twice-Weekly Enstilar Foam Safe and Effective for Long-Term Maintenance Treatment of Plaque Psoriasishttps://practicaldermatology.com/news/phase-3-study-finds-twice-weekly-enstilar-foam-safe-and-effective-for-long-term-maintenance-treatment-of-plaque-psoriasis/2460427/LEO Pharma A/S presented results from the Phase 3 PSO-LONG clinical tria, which compared the efficacy and safety of twice-weekly Enstilar (calcipotriene and betamethasone dipropionate) Foam versus foam vehicle for long-term (52-week) maintenance treatment for adult patients with plaque psoriasis.
- Further Evidence of Long-term Use and Cost-effectiveness of Ilumya for Psoriasis Presented at Virtual AADhttps://practicaldermatology.com/news/further-evidence-of-long-term-use-and-cost-effectiveness-of-ilumya-for-psoriasis-presented-at-virtual-aad/2460425/Sun Pharmaceutical Industries Ltd. presented further evidence of the long-term use and cost-effectiveness of tildrakizumab-asmn (Ilumya) in moderate to severe plaque psoriasis at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020. Long-term analyses of the reSURFA
- Late-Breaking Data: Lilly and Dermira’s Lebrikizumab Improves Itch, Sleep and Quality of Life in ADhttps://practicaldermatology.com/news/late-breaking-data-lilly-and-dermiras-lebrikizumab-improves-itch-sleep-and-quality-of-life-in-ad-1/2460424/Lilly and Dermira’s Lebrikizumab improves itch, sleep and quality of life in patients with moderate-to-severe atopic dermatitis (AD), according to a Phase 2b clinical trial presented during a virtual late-breaking, oral session at the American Academy of Dermatology (AAD) 2020 Annual Meetin
- Late-Breaking Data: Skyrizi Achieves Superior Rates of Complete Skin Clearance for Psoriasis Compared to Secukinumab at 52 Weekshttps://practicaldermatology.com/news/late-breaking-data-show-skyrizi-achieves-superior-rates-of-complete-skin-clearance-for-psoriasis-compared-to-secukinumab-at-52-weeks/2460423/New late-breaking Phase 3b head-to-head data show superior rates of skin clearance for AbbVie's risankizumab-rzaa (Skyrizi) compared to secukinumab (Cosentyx) at week 52. Sixty-six percent of psoriasis patients receiving Skyrizi achieved completely clear skin—100 percent clearance in th
- Dermavant Completes Enrollment for Long-Term Safety Study of Tapinarof in Adult Psoriasishttps://practicaldermatology.com/news/dermavant-completes-enrollment-for-long-term-safety-study-of-tapinarof-in-adult-psoriasis/2460416/Patient enrollment in Dermavant’s long-term safety study of tapinarof is now complete, the company says. Tapinarof is a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) being investigated for use in adult patients diagnosed with plaq
- Hoth Therapeutics Obtains Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/hoth-therapeutics-obtains-full-licensing-rights-for-biolexa-platform-atopic-dermatitis-treatment/2460397/Hoth Therapeutics, Inc. has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic dermatitis. This agreement serves as an extension to the previo
- Galderma: Patients Treated with Dysport Achieved High Levels of Satisfaction and Natural-Looking Results with Two Treatments Per Yearhttps://practicaldermatology.com/news/galderma-patients-treated-with-dysport-achieved-high-levels-of-satisfaction-and-natural-looking-results-with-two-treatments-per-year/2460391/Topline results of DREAM (Dysport Real-world Evaluation and Measured satisfaction study), a clinical study of Dysport (abobotulinumtoxinA) for injection, showed that 95 percent of patients treated with Dysport achieved high levels of satisfaction with two treat
- Accure Laser Gets CE Mark for Acne Treatmenthttps://practicaldermatology.com/news/accure-laser-gets-ce-mark-for-acne-treatment/2460386/Accure Acne, Inc. now has a European CE mark for its groundbreaking Accure Laser™ system to treat patients with moderate acne vulgaris. The Accure Laser is the first commercially-developed light-based platform in the world to selectively target and injure sebaceous glands. Fo
- Positive Top-Line Results Seen for Otezla in Mild-To-Moderate Plaque Psoriasishttps://practicaldermatology.com/news/positive-top-line-results-seen-for-otezla-in-mild-to-moderate-plaque-psoriasis/2460382/Amgen’s Otezla produces significant improvements in measures of mild-to-moderate psoriasis, compared with placebo, according to a top-line results from the ADVANCE trial. ADVANCE is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy o
- Supportive Oncodermatology Interventions Improve Patient Quality of Lifehttps://practicaldermatology.com/news/supportive-oncodermatology-interventions-improve-patient-quality-of-life-1/2460377/Enrollment in a supportive oncodermatology program is associated with a significantly improved quality of life score, according to a recent survey from the George Washington University (GW) Cancer Center. The